1. Home
  2. BLRX vs GSIW Comparison

BLRX vs GSIW Comparison

Compare BLRX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • GSIW
  • Stock Information
  • Founded
  • BLRX 2003
  • GSIW 2016
  • Country
  • BLRX Israel
  • GSIW Hong Kong
  • Employees
  • BLRX N/A
  • GSIW N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • GSIW
  • Sector
  • BLRX Health Care
  • GSIW
  • Exchange
  • BLRX Nasdaq
  • GSIW Nasdaq
  • Market Cap
  • BLRX 12.2M
  • GSIW 12.3M
  • IPO Year
  • BLRX 2011
  • GSIW 2023
  • Fundamental
  • Price
  • BLRX $3.10
  • GSIW $0.48
  • Analyst Decision
  • BLRX Buy
  • GSIW
  • Analyst Count
  • BLRX 2
  • GSIW 0
  • Target Price
  • BLRX $26.00
  • GSIW N/A
  • AVG Volume (30 Days)
  • BLRX 26.4K
  • GSIW 91.3K
  • Earning Date
  • BLRX 05-27-2025
  • GSIW 12-31-2024
  • Dividend Yield
  • BLRX N/A
  • GSIW N/A
  • EPS Growth
  • BLRX N/A
  • GSIW N/A
  • EPS
  • BLRX N/A
  • GSIW N/A
  • Revenue
  • BLRX $28,940,000.00
  • GSIW $1,313,795.00
  • Revenue This Year
  • BLRX N/A
  • GSIW N/A
  • Revenue Next Year
  • BLRX N/A
  • GSIW N/A
  • P/E Ratio
  • BLRX N/A
  • GSIW N/A
  • Revenue Growth
  • BLRX 502.92
  • GSIW N/A
  • 52 Week Low
  • BLRX $2.85
  • GSIW $0.43
  • 52 Week High
  • BLRX $35.60
  • GSIW $12.30
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 41.70
  • GSIW 47.04
  • Support Level
  • BLRX $3.01
  • GSIW $0.45
  • Resistance Level
  • BLRX $3.61
  • GSIW $0.52
  • Average True Range (ATR)
  • BLRX 0.22
  • GSIW 0.03
  • MACD
  • BLRX 0.02
  • GSIW 0.00
  • Stochastic Oscillator
  • BLRX 32.89
  • GSIW 58.82

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

Share on Social Networks: